EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy‐Responsive Locally Advanced Rectal Adenocarcinoma

Gertruda Evaristo iD, Carla Harmath, Jeremy P Segal, Ardaman Shergill, Namrata Setia

Cancer Reports · 2024-12 · 7 (12)

DOI: 10.1002/cnr2.70037 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, online erschienen am 18.12.2024. Verfasst von Gertruda Evaristo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: MutS Homolog 2 Protein, Adenocarcinoma, Germ-Line Mutation, Mutation, Missense. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rapid and accurate identification of mismatch repair (MMR) deficiency and Lynch syndrome is critical in the prognostication and clinical management of patients with colorectal carcinoma. Case Description We describe here a young woman who developed a locally aggressive rectal adenocarcinoma with intact MMR protein expression by immunohistochemistry and absence of histologic evidence of MMR deficiency‐associated increased tumoral immune response. Germline DNA‐targeted sequencing identified MSH2 variant p.R711P, initially classified as a variant of undetermined significance. Somatic tumoral DNA analysis revealed the identical MSH2 variant, high tumor mutational burden, and microsatellite instability, in addition to superimposed alterations in β2‐microglobulin gene, possibly explaining the altered intratumoral immunity. Consequently, the patient was started on immunotherapy, leading to successful disease control (33 month follow‐up).

Conclusion

The findings emphasize the utility of an integrative approach in the assessment of MMR status for determining candidacy for immunotherapy, especially in the setting of missense variants in MMR genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutS Homolog 2 ProteinAdenocarcinomaGerm-Line MutationMutation, MissenseRectal NeoplasmsHumansFemaleAdultMicrosatellite InstabilityImmunotherapyDNA Mismatch RepairColorectal Neoplasms, Hereditary Nonpolyposis

Stichwörter der Autor:innen

colorectal cancercrcimmunotherapymmrmsirectal cancer

Substanzen

MutS Homolog 2 ProteinMSH2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, The University of Chicago, Chicago, Illinois, USA.
  • Department of Radiology, The University of Chicago, Chicago, Illinois, USA.
  • Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Gertruda Evaristo

Zitieren

APA

Evaristo, G., Harmath, C., Segal, J. P., Shergill, A., & Setia, N. (2024). Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy‐Responsive Locally Advanced Rectal Adenocarcinoma. Cancer Reports, 7(12). https://doi.org/10.1002/cnr2.70037

Vancouver

Evaristo G, Harmath C, Segal JP, Shergill A, Setia N. Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy‐Responsive Locally Advanced Rectal Adenocarcinoma. Cancer Reports. 2024;7(12). doi:10.1002/cnr2.70037

BibTeX
@article{Evaristo2024,
  author = {Evaristo, Gertruda and Harmath, Carla and Segal, Jeremy P and Shergill, Ardaman and Setia, Namrata},
  title = {Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy‐Responsive Locally Advanced Rectal Adenocarcinoma},
  journal = {Cancer Reports},
  year = {2024},
  volume = {7},
  number = {12},
  doi = {10.1002/cnr2.70037}
}
Kostenlos starten →